The Progressive Reduction in the Ovarian Reserve in Young Women After Anticancer Treatment

 

 Permissions and Reprints

Abstract

Anticancer treatment can disturb gonadal function and deplete the primordial follicle pool, leading to premature menopause. We made a prospective analysis of serum hormone levels in young female cancer survivors who had been treated during childhood and adolescence. Serum anti-Müllerian hormone (AMH) as a marker of ovarian reserve, FSH, LH, and estradiol were measured in 33 women treated previously (6–11 years earlier) for Hodgkin Lymphoma, solid tumours, and after bone marrow transplantation, and in 34 healthy controls. The group of survivors was divided according to the risk of gonadotoxicity into the low risk and median risk group (LR+MR), and into the high risk (HR) group. The measurements were repeated after 5 years. In the HR group, AMH levels were significantly lower than in controls (p=0.001) and in the LR+MR group (p=0.006) at the time of the first examination fell progressively after 5 years (p=0.03), whereas elevated FSH values (p=0.053) increased (p=0.001). Unchanged LH values in the first measurement rose in the second one (p=0.001). In the LR+MR group, the levels of AMH and FSH were normal (compared to the control) at baseline, but after 5 years serum AMH decreased (p=0.027) and FSH increased (p=0.008). Our findings indicate that anticancer treatment during childhood and adolescence is associated with a serious, progressive risk of ovarian failure. It is necessary to inform female cancer survivors, especially the high risk patients, about the risk of premature menopause.

• References

• 1 Brougham MF, Wallace WH. Subfertility in children and young people treated for solid and haematological malignancies. Br J Haematol 2005; 131: 143-155
  PubMedGoogle Scholar
• 2 Bath LE, Anderson RA, Critchley HO, Kelnar CJ, Wallace WH. Hypothalamic-pituitary-ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia. Hum Reprod 2001; 16: 1838-1844
  CrossrefPubMedGoogle Scholar
• 3 Green DM, Sklar CA, Boice Jr JD, Mulvihill JJ, Whitton JA, Stovall M, Yasui Y. Ovarian Failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2374-2381
  CrossrefPubMedGoogle Scholar
• 4 Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 2005; 11: 69-89
  PubMedGoogle Scholar
• 5 Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered?. Lancet Oncol 2005; 6: 209-218
  CrossrefPubMedGoogle Scholar
• 6 Anderson RA, Nelson SM, Wallace WH. Measuring anti-Müllerian hormone for the assessment of ovarian reserve: when and for whom is it indicated?. Maturitas 2012; 71: 28-33
  CrossrefPubMedGoogle Scholar
• 7 Hagen CP, Aksglaede L, Sorensen K, Hagen C, Main KM, Boas M, Cleemann L, Holm K, Gravholt CH, Andersson AM, Pedersen AT, Petersen JH, Linneberg A, Kjaergaard S, Juul A. Serum Levels of Anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab 2010; 95: 5003-5010
  CrossrefPubMedGoogle Scholar
• 8 Broer SL, Eijkemans MJ, Scheffer GJ, van Rooij IA, de vet A, Themmen AP, Laven JS, de jong FH, Te Velde ER, Fauser BC, Broekmans FJ. Anti-Müllerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metabol 2011; 96: 2532-2539
  CrossrefPubMedGoogle Scholar
• 9 Krawczuk-Rybak M, Leszczynska E, Wysocka J, Zelazowska-Rutkowska B. Anti-Müllerian hormone in young women after chemotherapy and infradiaphragmatic radioterapy for childhood cancer. Pediatr Endocrinol Diabetes Metab 2008; 14: 99-103
  PubMedGoogle Scholar
• 10 Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, Robison LL, Sklar CA. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 2006; 91: 1723-1728
  CrossrefPubMedGoogle Scholar
• 11 Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, Mulder J, Green D, Nicholson HS, Yasui Y, Robison LL. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006; 98: 890-896
  CrossrefPubMedGoogle Scholar
• 12 Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 2003; 88: 5307-5314
  CrossrefPubMedGoogle Scholar
• 13 Lie Fong S, Laven JS, Hakvoort-Cammel FG, Schipper I, Visser JA, Themmen AP, de jong FH, van den Heuvel-Eibrink MM. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. Hum Reprod 2009; 24: 982-990
  CrossrefPubMedGoogle Scholar
• 14 Loverro G, Guarini A, Di Naro E, Giacomantonio L, Lavopa C, Liso V. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007; 12: 141-147
  CrossrefPubMedGoogle Scholar
• 15 Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003; 18: 2368-2374
  CrossrefPubMedGoogle Scholar
• 16 Ahmed Ebbiary NA, Lenton EA, Cooke ID. Hypothalamic-pituitary agenting: progressive increase in FSH and LH concentrations throughout the reproductive life in regularly menstruating women. Clin Endocrinol (Oxf) 1994; 41: 199-206
  CrossrefPubMedGoogle Scholar
• 17 van Rooij IA, Id Tonkelaar, Broekmans FJ, Looman CW, Scheffer GJ, de Jong FH, Themmen AP, te Velde ER. Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 2004; 11: 601-606
  CrossrefPubMedGoogle Scholar
• 18 van Beek RD, van den Heuvel-Eibrink MM, Laven JS, de Jong FH, Themmen AP, Hakvoort-Cammel FG, van den Bos C, van den Berg H, Pieters R, de Muinck Keizer-Schrama SM. Anti-Müllerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin’s lymphoma during childhood. J Clin Endocrinol Metab 2007; 92: 3869-3874
  CrossrefPubMedGoogle Scholar
• 19 Welt CK, Hall JE, Adams JM, Taylor AE. Relationship of estradiol and inhibin B to the follicle – stimulating hormone variability in hypergonadotropic hypogonadism or premature ovarian failure. J Clin Endocrinol Metab 2005; 90: 826-830
  CrossrefPubMedGoogle Scholar
• 20 Franchi-Rezgui P, Rousselot P, Espié M, Brière J, Pierre Marolleau J, Gisselbrecht C, Brice P. Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas. Hematol J 2003; 4: 116-120
  CrossrefPubMedGoogle Scholar
• 21 De Bruin ML, Huisbrink J, Hauptmann M, Kuenen MA, Ouwens GM, van’t Veer MB, Aleman BM, van Leeuwen FE. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008; 111: 101-108
  CrossrefPubMedGoogle Scholar
• 22 Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A. German Hodgkin’s Lymphoma Study Group . Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2005; 23: 7555-7564
  CrossrefPubMedGoogle Scholar
• 23 Hamre H, Kiserud CE, Ruud E, Thorsby PM, Fossa SD. Gonadal function and parenthood 20 years after treatment for childhood lymphoma: A Cross-Sectional Study. Pediatr Blood Cancer 2012; 59: 271-277
  CrossrefPubMedGoogle Scholar
• 24 Brougham MF, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WH. Anti-Müllerian Hormone Is a Marker of Gonadotoxicity in Pre- and Postpubertal Girls Treated for Cancer: A Prospective Study. J Clin Endocrinol Metab 2012; 97: 2059-2067
  CrossrefPubMedGoogle Scholar
• 25 Schuck A, Hamelmann V, Brämswig JH, Könemann S, Rübe C, Hesselmann S, Riesenbeck D, Horst E, Bölling T, Paulussen M, Jürgens H, Willich N. Ovarian function following pelvic irradiation in prepubertal and pubertal girls and young adult women. Strahlenther Onkol 2005; 181: 534-539
  CrossrefPubMedGoogle Scholar
• 26 Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod 2003; 18: 117-121
  CrossrefPubMedGoogle Scholar
• 27 Lie Fong S, Lugtenburg PJ, Schipper I, Themmen AP, de Jong FH, Sonneveld P, Laven JS. Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod 2008; 23: 674-678
  CrossrefPubMedGoogle Scholar
• 28 Borgmann-Staudt A, Rendtorff R, Reinmuth S, Hohmann C, Keil T, Schuster FR, Holter W, Ehlert K, Keslova P, Lawitschka A, Jarisch A, Strauss G. Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence. Bone Marrow Transplant 2012; 47: 271-276
  CrossrefPubMedGoogle Scholar
• 29 Larsen EC, Muller J, Rechnitzer C, Schmiegelow K, Andersen AN. Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH<10 IU/l. Hum Reprod 2003; 18: 417-422
  CrossrefPubMedGoogle Scholar
• 30 Lantinga GM, Simons AH, Kamps WA, Postma A. Imminent ovarian failure in childhood cancer survivors. Eur J Cancer 2006; 42: 1415-1420
  CrossrefPubMedGoogle Scholar
• 31 Balcerek M, Reinmuth S, Hohmann C, Keil T, Borgmann-Staudt A. Suspected Infertility After Treatment for Leukemia and Solid Tumors in Childhood and Adolescence. Dtsch Arztebl Int 2012; 109: 126-131
  PubMedGoogle Scholar
• 32 Mörse H, Elfving M, Lindgren A, Wölner-Hanssen P, Andersen CY, Øra I. Acute onset of ovarian dysfunction in young females after start of cancer treatment. Pediatr Blood Cancer 2013; 60: 676-681
  CrossrefPubMedGoogle Scholar